Conference
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
Authors
Ellis PM; Liu G; Millward M; Perrone F; Shepherd FA; Sun S; Cho BC; Morabito A; Stockler MR; Wierzbicki R
Volume
32
Pagination
pp. 8036-8036
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.8036
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X